NOW YOU MAY BE ABLE TO START WITH SCEMBLIX
As of October 2024, SCEMBLIX is now approved for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Ask your doctor if SCEMBLIX may be right for you.
The approval of SCEMBLIX in patients newly diagnosed is based on a study that measured major molecular response (MMR) rate. There are ongoing studies to confirm the clinical benefit of SCEMBLIX for this use and how SCEMBLIX works over a longer period of time.
ANYTHING BUT
A STRAIGHT LINE
SCEMBLIX is for those whose journey has had its ups and downs